Literature DB >> 15978767

Mechanistic explanation to the catalysis by pyrazinamide and ethambutol of reaction between rifampicin and isoniazid in anti-TB FDCs.

Hemant Bhutani1, Saranjit Singh, K C Jindal, Asit K Chakraborti.   

Abstract

Rifampicin and isoniazid are known to interact with each other in solid formulation environment to yield isonicotinyl hydrazone (HYD). In earlier studies, this reaction was indicated to be catalyzed by pyrazinamide and ethambutol hydrochloride, the two other co-drugs present in oral anti-tuberculosis fixed-dose combination (FDC) formulations. Accordingly, the present study was carried out to understand the catalytic role of pyrazinamide and ethambutol hydrochloride on the reaction between rifampicin and isoniazid. For the purpose, organic bases and amides similar in structure to pyrazinamide and ethambutol hydrochloride were combined individually with rifampicin and isoniazid. The compounds employed were pyrazine, piperdine, pyrollidine, pyridine, triethylamine, diisopropylethylamine, picolinamide, benzamide, ethylenediamine, ethanolamine, diethanolamine, and triethanolamine. An additional study was also carried out in the presence of free base of ethambutol. The mixtures were exposed to accelerated stability test condition of 40 degrees C/75% RH for 15 d. The nature of the products formed and the changes in relative concentrations of the drugs and products were followed by HPLC. The drugs showed different extent of degradation, yielding HYD, and in some cases degradation products of rifampicin. The results confirmed the catalytic role of pyrazinamide and ethambutol hydrochloride. The catalysis is postulated to involve intra-molecular proton transfer during transhydrazone formation process, entailing a tetrahedral mechanism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15978767     DOI: 10.1016/j.jpba.2005.05.015

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  4 in total

Review 1.  Challenges and opportunities in achieving bioequivalence for fixed-dose combination products.

Authors:  Amitava Mitra; Yunhui Wu
Journal:  AAPS J       Date:  2012-06-09       Impact factor: 4.009

2.  A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection.

Authors:  John Gar Yan Chan; Anneliese S Tyne; Angel Pang; Hak-Kim Chan; Paul M Young; Warwick J Britton; Colin C Duke; Daniela Traini
Journal:  Pharm Res       Date:  2013-11-16       Impact factor: 4.200

3.  Bisoprolol and bisoprolol-valsartan compatibility studied by differential scanning calorimetry, nuclear magnetic resonance and X-ray powder diffractometry.

Authors:  Marcin Skotnicki; Juan A Aguilar; Marek Pyda; Paul Hodgkinson
Journal:  Pharm Res       Date:  2014-08-13       Impact factor: 4.200

4.  Synthesis, spectral and solid state characterization of a new bioactive hydrazine bridged cyclic diphosphonium compound.

Authors:  Milica Milenković; Beata Warżajtis; Urszula Rychlewska; Dušanka Radanović; Katarina Anđelković; Tatjana Božić; Miroslava Vujčić; Dušan Sladić
Journal:  Molecules       Date:  2012-03-02       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.